Cphpc
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
224624-80-0O=C(O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)OHZLAWYIBLZNRFZ-VXGBXAGGSA-NMiridesap has been used in trials studying the prevention of HIV and treatment of AL amyloidosis.
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P264, P264+P265, P270, P280, P301+P317, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P317, P321, P330, P363, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
説明Serum amyloid P (SAP) is pentraxin with roles in inflammation and immune response. CPHPC is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance. It also produces significant reduction of SAP from cerebrospinal fluid and visceral amyloid deposits. CPHPC has been used with anti-SAP antibodies to eliminate amyloid deposits in clinical trials of systemic amyloidosis.
使用Miridesap is a potential drug in the treatment of amyloidosis.
224624-80-0DTXSID00176996CHEMBL25263